Details for Patent: 7,709,517

Which drugs does patent 7,709,517 protect, and when does it expire?

Patent 7,709,517 protects XTANDI and is included in two NDAs.

This patent has one hundred and thirty-three patent family members in twenty-eight countries.

Summary for Patent: 7,709,517

Title:	Diarylhydantoin compounds
Abstract:	The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.
Inventor(s):	Sawyers; Charles L. (New York, NY), Jung; Michael E. (Los Angeles, CA), Chen; Charlie D. (Los Angeles, CA), Ouk; Samedy (Costa Mesa, CA), Welsbie; Derek (Northridge, CA), Tran; Chris (New York, NY), Wongvipat; John (Nanuet, NY), Yoo; Dongwon (Los Angeles, CA)
Assignee:	The Regents of the University of California (Oakland, CA)
Application Number:	11/433,829
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,709,517
Patent Claim Types: see list of patent claims	Compound; Composition;

Drugs Protected by US Patent 7,709,517

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Astellas	XTANDI	enzalutamide	CAPSULE;ORAL	203415-001	Aug 31, 2012		RX	Yes	Yes			Y	Y
Astellas	XTANDI	enzalutamide	TABLET;ORAL	213674-001	Aug 4, 2020		RX	Yes	No			Y	Y
Astellas	XTANDI	enzalutamide	TABLET;ORAL	213674-002	Aug 4, 2020		RX	Yes	Yes			Y	Y

International Family Members for US Patent 7,709,517

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	541571
Australia	2006248109
Australia	2007245022
Brazil	PI0610359
Brazil	PI0709682
Canada	2608436